Navigation Links
CardioInsight Announces Addition of Jim Hassett to Senior Management Team
Date:2/28/2012

CLEVELAND, Feb. 28, 2012 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the appointment of Jim Hassett as its Vice President of Clinical Affairs.

(Logo:  http://photos.prnewswire.com/prnh/20110531/DC10432LOGO)

Mr. Hassett brings more than 30 years of product development, clinical development and regulatory affairs experience in the field of cardiac rhythm management to CardioInsight.  His previous roles include senior management level positions in clinical and therapy development, most notably at Daig Corporation and subsequently at St Jude Medical, where he held Vice President positions in the AF Division.  Mr. Hassett has successfully managed the development and clinical introduction of a number of innovative electrophysiology products that include cardiac mapping, arrhythmia ablation, and heart failure devices.

"I have been aware of CardioInsight's technology for a number of years, and have been impressed with its development into a commercial product," said Mr. Hassett.  "The ECVUE™  system addresses a clear unmet need in the treatment of arrhythmias and other electrical disorders of the heart, and I look forward to helping make this system a valuable clinical tool in everyday electrophysiology practice."

CardioInsight recently announced the commercial introduction of its ECVUE non-invasive cardiac mapping system in Europe, and is working to demonstrate the clinical utility of the system in a commercial setting.   In the coming year, the Company will pursue regulatory clearance in the U.S., as well as accelerate its clinical development efforts to further validate its unique ability to simplify cardiac mapping procedures, reduce procedure times, and expand the use of mapping to new applications, including cardiac resynchronization therapy (CRT).

"Jim's extensive clinical development experience, coupled with his strong reputation working with the FDA and clinical thought leaders throughout the world will be an invaluable asset as we accelerate our clinical development," said Steve Arless, CardioInsight's Chief Executive Officer. "The ability to attract someone of Jim's caliber is further validation of the potential of the ECVUE system, and CardioInsight's continued evolution to a commercial stage company."

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart.
 The images help physicians more accurately treat certain heart ailments such as arrhythmias
and congestive heart failure. The Company's ECVUE system non-invasively generates real-time, whole heart images of
the electrical activity on the surface of the heart by combining body surface electrical data with
3D anatomical data obtained from imaging scans. It then reconstructs and
displays 3D images and other useful measures of cardiac electrical activity as if the
measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hospital Cardiologique Haut Leveque in Bordeaux, France.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system.  Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences.  The Company has received its CE Mark and markets the ECVUE system in Europe.

For more information, visit CardioInsight's website at www.cardioinsight.com, or contact us at 216-453-5950.


'/>"/>
SOURCE CardioInsight Technologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 19, 2016 A new report ... Market -Opportunities and Forecasts, 2015 -2022, projects that the ... 2022, registering a CAGR of 5.1% from 2015 to ... be the highest revenue-generating segment throughout the forecast period. ... one-third of the market share in 2015, and is ...
(Date:5/19/2016)... -- The equities market is never short of ... is without doubt the Healthcare space. ActiveWallSt.com has uncovered four ... Alkermes PLC (NASDAQ: ALKS ), AMAG Pharmaceuticals Inc. ... IDXX ), and Atossa Genetics Inc. (NASDAQ: ... http://www.activewallst.com/ On Wednesday, Alkermes PLC,s ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... The old expression “a ... problem. A common injury that’s often misunderstood, whiplash should be swiftly diagnosed and treated ... orthopedic spine surgeon at Atlantic Spine Center . , So named because ...
(Date:5/24/2016)... ... 24, 2016 , ... Researchers from Catholic Health Initiatives (CHI) ... bleeding complications from percutaneous coronary intervention (PCI). The data, presented at the annual ... document a 40% reduction in risk-adjusted bleeding event rates over a two-year period ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... web-based software module. The cutting-edge feature provides end users with an embedded, ... self-service business intelligence solution and its analytics engine. , This powerful ...
(Date:5/23/2016)... Akron, Ohio (PRWEB) , ... May 23, 2016 ... ... not-for-profit continuing care retirement community, dedicated its new $11.5 million, 64-room assisted living ... an invitation-only ceremony and ribbon cutting. , The new building provides the ...
(Date:5/23/2016)... ... May 23, 2016 , ... According to an article ... than 1% of United Kingdom residents who could benefit from bariatric surgery are actually ... increases the number of bariatric procedures it offers to obese patients from 6,000 to ...
Breaking Medicine News(10 mins):